Welcome to our dedicated page for Tempus AI news (Ticker: TEM), a resource for investors and traders seeking the latest updates and insights on Tempus AI stock.
Tempus AI, Inc. (NASDAQ: TEM) is a healthcare technology company that applies artificial intelligence and multimodal data to precision medicine, with a strong focus on oncology and health information services. The Tempus news stream highlights how the company’s platform, genomic testing capabilities, and data-driven tools are used in collaborations, research, and commercial partnerships.
Readers can follow announcements about Tempus’s strategic collaborations with leading health systems and academic medical centers, such as multi-year precision oncology initiatives and efforts to expand access to genomic testing for cancer patients. News items also cover research partnerships with nonprofit foundations, including multi-omic studies designed to build comprehensive datasets for specific diseases like follicular lymphoma.
Tempus frequently reports on its participation in major scientific conferences, where it presents abstracts based on its de-identified multimodal database and tools like Tempus Lens. These updates include studies on tumor genomics, immune microenvironments, biomarkers, and real-world outcomes across a range of cancers, including gastrointestinal, breast, and other solid tumors. In addition, the news feed features corporate and financial updates, such as preliminary revenue results, contract value milestones, and appearances at investor conferences.
By reviewing the latest TEM news, investors and healthcare professionals can see how Tempus’s AI-enabled precision medicine solutions are being applied in clinical settings, research collaborations, and life sciences partnerships. This page is a resource for tracking ongoing developments in Tempus’s diagnostics, data and applications businesses, as well as its role in advancing data-driven approaches to cancer care and therapeutic development.
Tempus AI (NASDAQ: TEM) has announced a collaboration with United Therapeutics (UT) to develop AI-based medical device software for early detection of pulmonary hypertension (PH). This fatal heart and lung condition affects around 1% of the population. Despite available treatments, PH diagnosis is typically delayed by over two years. Tempus' AI algorithm, which analyzes ECG results to identify at-risk patients, was presented at the American Thoracic Society International Conference. The algorithm will be deployed in a prospective clinical study at up to 60 centers. Tempus aims to engage with the FDA for regulatory alignment.
Tempus AI announced the pricing of its initial public offering (IPO) of 11,100,000 shares of Class A common stock at $37.00 per share.
The gross proceeds are expected to be $410.7 million, before deducting underwriting discounts, commissions, and other expenses.
The underwriters have a 30-day option to purchase an additional 1,665,000 shares.
The shares will trade on the Nasdaq Global Select Market under the ticker symbol "TEM" starting June 14, 2024, with the offering expected to close on June 17, 2024.
Morgan Stanley, J.P. Morgan, and Allen & Company are the lead book-running managers, with BofA Securities and TD Cowen also participating.
Stifel, William Blair, Loop Capital Markets, and Needham & Company are co-managers.
The SEC declared the registration statement effective on June 13, 2024.